Nov 19 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES POSITIVE ONE YEAR CHALLENGE RESULTS FROM PRECLINICAL STUDY EVALUATING BIODEFENSE VACCINE CANDIDATE ATI-1701 AND CHANGE TO BOARD OF DIRECTORS
* APPILI THERAPEUTICS INC - JOSEF VEJVODA HAS RESIGNED FROM COMPANY'S BOARD OF DIRECTORS
* APPILI THERAPEUTICS - MAKING CONTINUED PROGRESS ON MANUFACTURING AND IND-ENABLING ACTIVITIES TO ADVANCE ATI-1701 INTO CLINIC
Source text for Eikon: ID:nBwbPQ2TRa Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))